UiPath (NYSE:PATH) Trading Up 0.5%

Shares of UiPath Inc. (NYSE:PATH) rose 0.5% during mid-day trading on Friday . The stock traded as high as $19.75 and last traded at $19.50. Approximately 1,296,716 shares were traded during trading, a decline of 85% from the average daily volume of 8,657,022 shares. The stock had previously closed at $19.41.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Mizuho upped their price objective on UiPath from $22.00 to $25.00 and gave the company a “neutral” rating in a report on Thursday, March 14th. Barclays raised their price objective on shares of UiPath from $23.00 to $25.00 and gave the company an “equal weight” rating in a research report on Friday, March 15th. Wells Fargo & Company boosted their target price on shares of UiPath from $24.00 to $25.00 and gave the stock an “equal weight” rating in a report on Thursday, March 14th. TD Cowen raised their target price on shares of UiPath from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, March 14th. Finally, BMO Capital Markets upped their price target on UiPath from $24.00 to $28.00 and gave the company a “market perform” rating in a report on Thursday, March 14th. Nine research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, UiPath presently has an average rating of “Moderate Buy” and a consensus price target of $27.41.

UiPath Price Performance

The stock’s 50 day simple moving average is $22.30 and its two-hundred day simple moving average is $21.53. The company has a market capitalization of $11.07 billion, a P/E ratio of -114.70 and a beta of 0.96.

UiPath (NYSE:PATH) last posted its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.10. The business had revenue of $405.25 million during the quarter, compared to analysts’ expectations of $383.32 million. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. As a group, equities research analysts expect that UiPath Inc. will post -0.04 earnings per share for the current year.

Insider Activity at UiPath

In other news, CFO Ashim Gupta sold 40,000 shares of the company’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $21.66, for a total transaction of $866,400.00. Following the completion of the transaction, the chief financial officer now directly owns 660,762 shares in the company, valued at $14,312,104.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders have sold 72,000 shares of company stock worth $1,591,360. Corporate insiders own 31.03% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Royal London Asset Management Ltd. raised its holdings in shares of UiPath by 5.9% in the 3rd quarter. Royal London Asset Management Ltd. now owns 139,544 shares of the healthcare company’s stock valued at $2,388,000 after acquiring an additional 7,742 shares in the last quarter. O Shaughnessy Asset Management LLC purchased a new stake in shares of UiPath in the 3rd quarter worth about $203,000. Invesco Ltd. raised its stake in UiPath by 2.8% during the third quarter. Invesco Ltd. now owns 399,181 shares of the healthcare company’s stock valued at $6,830,000 after buying an additional 10,863 shares during the last quarter. Symmetry Partners LLC bought a new position in shares of UiPath in the fourth quarter worth approximately $205,000. Finally, Toroso Investments LLC increased its holdings in UiPath by 196.7% in the 3rd quarter. Toroso Investments LLC now owns 78,189 shares of the healthcare company’s stock worth $1,338,000 after buying an additional 51,834 shares in the last quarter. 62.50% of the stock is owned by institutional investors.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.